Download PDF
CC BY 4.0 · World J Nucl Med 2023; 22(01): 007-014
DOI: 10.1055/s-0042-1751053
Original Article

Utility of 99mTechnetium Pertechnetate Thyroid Scan and Uptake in Thyrotoxic Patients: Jordanian Experience

Kusai M. Al-Muqbel
1   Faculty of Medicine, Department of Radiology and Nuclear Medicine, Jordan University of Science and Technology, Irbid, Jordan
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Objective The objective of this study was to assess our local experience with 99mTechnitium thyroid uptake (TcTU) in thyrotoxicosis by examining mean and range of TcTU in both euthyroid patients and thyrotoxic patients. We also wanted to see how well TcTU performed as a substitute for radioiodine thyroid uptake in thyrotoxicosis.

Methods The medical records of thyrotoxic patients were reviewed retrospectively. Inclusion criteria were: (1) thyrotoxicosis was proven biochemically, (2) the patient underwent TcTU at the time of thyrotoxicosis diagnosis, (3) at least 6 months of follow-up, and (4) the final diagnosis was documented. All TcTU of euthyroid patients were also reviewed to determine local normal TcTU mean and range. Patients were divided into three groups: Graves' disease, toxic nodular goiter, and subacute thyroiditis. Each patient group's TcTU mean and range were assessed separately.

Results There were 209 patients in total (54 euthyroid, 112 Graves' disease, 26 toxic nodules, and 17 patients with subacute thyroiditis). TcTU mean±standard deviation and range for euthyroid patients were 1.5±1.1% and 0.17 to 4.8%, 10.6±10% and 0.43 to 40% for Graves' disease, 4.5±4% and 0.6 to 15% for toxic nodules, and 0.5±0.4% and 0.18 to 1% for subacute thyroiditis. Although one-third of thyrotoxic patients' TcTU values overlapped with the normal TcTU range, the diagnosis was made using qualitative image analysis. Subacute thyroiditis was characterized by poor thyroid visualization, whereas Graves'/toxic nodular goiter was well visualized.

Conclusion The mean and range of our local normal TcTU were similar to those previously published. TcTU was a useful alternative to radioiodine in the evaluation of thyrotoxicosis. About two-thirds of the patients had accurate test results. The diagnosis was reached in the remaining one-third of patients by combining quantitative and qualitative image features. This method allowed us to stop giving radioiodine to our patients, resulting in a significant reduction in patient radiation exposure.

Keywords

thyroid uptake - technetium-99m - thyrotoxicosis - radioiodine - Graves' disease - toxic nodular goiter


Publication History

Article published online:
02 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Macauley M, Shawgi M, Ali T. et al. Assessment of normal reference values for thyroid uptake of technetium-99m pertechnetate in a single centre UK population. Nucl Med Commun 2018; 39 (09) 834-838
    CrossrefPubMedGoogle Scholar
  • 2 Al-Muqbel KM, Tashtoush RM. Patterns of thyroid radioiodine uptake: Jordanian experience. J Nucl Med Technol 2010; 38 (01) 32-36
    CrossrefPubMedGoogle Scholar
  • 3 Atkins HL. Technetium-99m pertechnetate uptake and scanning in the evaluation of thyroid function. Semin Nucl Med 1971; 1 (03) 345-355
    CrossrefPubMedGoogle Scholar
  • 4 Sucupira MS, Camargo EE, Nickoloff EL, Alderson PO, Wagner Jr HN. The role of 99mTc pertechnetate uptake in the evaluation of thyroid function. Int J Nucl Med Biol 1983; 10 (01) 29-33
    CrossrefPubMedGoogle Scholar
  • 5 Uchida T, Suzuki R, Kasai T. et al. Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study. Endocr J 2016; 63 (02) 143-149
    CrossrefPubMedGoogle Scholar
  • 6 Ikekubo K, Hino M, Ito H. et al. Thyrotoxic Graves' disease with normal thyroidal technetium-99m pertechnetate uptake. Ann Nucl Med 1990; 4 (02) 43-48
    CrossrefPubMedGoogle Scholar
  • 7 Ramos CD, Zantut Wittmann DE, Etchebehere EC, Tambascia MA, Silva CA, Camargo EE. Thyroid uptake and scintigraphy using 99mTc pertechnetate: standardization in normal individuals. Sao Paulo Med J 2002; 120 (02) 45-48
    CrossrefPubMedGoogle Scholar
  • 8 Maisey MN, Natarajan TK, Hurley PJ, Wagner Jr HN. Validation of a rapid computerized method of measuring 99mTc pertechnetate uptake for routine assessment of thyroid structure and function. J Clin Endocrinol Metab 1973; 36 (02) 317-322
    CrossrefPubMedGoogle Scholar
  • 9 Schneider PB. Simple, rapid thyroid function testing with 99mTc-pertechnetate thyroid uptake ratio and neck/thigh ratio. AJR Am J Roentgenol 1979; 132 (02) 249-253
    CrossrefPubMedGoogle Scholar
  • 10 Kidokoro-Kunii Y, Emoto N, Cho K, Oikawa S. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease. J Nippon Med Sch 2006; 73 (01) 10-17
    CrossrefPubMedGoogle Scholar
  • 11 Hays MT, Berman M. Pertechnetate distribution in man after intravenous infusion: a compartmental model. J Nucl Med 1977; 18 (09) 898-904
    PubMedGoogle Scholar
  • 12 Mettler Jr. FA, Guiberteau MJ. Essentials of Nuclear Medicine Imaging. 6th edition.. Saunders; Philadelphia, PA: 2012
    Google Scholar